{"transactions":[{"id":950683,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70279,"kind":"person","name":"SINGLETON J MATTHEW","position":1,"cik":"0001243514","reported_name":"SINGLETON J MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-05T20:26:57.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":20400,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":20400,"derivative":{"exercise_price":35.42,"exercise_date":"2027-01-02","expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":20400},"source":{"system":"sec-edgar","filing":"0001193125-26-003112","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1243514/000119312526003112/ownership.xml","form_type":"4"}},{"id":950682,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70279,"kind":"person","name":"SINGLETON J MATTHEW","position":1,"cik":"0001243514","reported_name":"SINGLETON J MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2026-01-05T20:26:57.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":3150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award (\"RSU\") of common stock under the Issuer's 2024 Equity Incentive Plan. All shares subject to the RSU shall vest on the one year anniversary of the grant date of the award."}],"balance_after":12650,"source":{"system":"sec-edgar","filing":"0001193125-26-003112","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1243514/000119312526003112/ownership.xml","form_type":"4"}},{"id":1310126,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70279,"kind":"person","name":"SINGLETON J MATTHEW","position":1,"cik":"0001243514","reported_name":"SINGLETON J MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-06T20:13:34.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":18800,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":18800,"derivative":{"exercise_price":41.12,"exercise_date":"2026-01-02","expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":18800},"source":{"system":"sec-edgar","filing":"0000950170-25-002483","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1243514/000095017025002483/ownership.xml","form_type":"4"}},{"id":1381236,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70279,"kind":"person","name":"SINGLETON J MATTHEW","position":1,"cik":"0001243514","reported_name":"SINGLETON J MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-25T19:27:22.000Z","date":"2024-10-25","kind":"exercise","planned":true,"acquired":false,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person."}],"balance_after":0,"derivative":{"exercise_price":4.48,"exercise_date":"2019-01-02","expiration_date":"2028-01-02","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0000950170-24-117513","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1243514/000095017024117513/ownership.xml","form_type":"4"}},{"id":1381235,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70279,"kind":"person","name":"SINGLETON J MATTHEW","position":1,"cik":"0001243514","reported_name":"SINGLETON J MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-10-25T19:27:22.000Z","date":"2024-10-25","kind":"sale","planned":true,"acquired":false,"shares":16000,"price":79.5,"value":1272000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person."}],"balance_after":9500,"source":{"system":"sec-edgar","filing":"0000950170-24-117513","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1243514/000095017024117513/ownership.xml","form_type":"4"}},{"id":1381234,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70279,"kind":"person","name":"SINGLETON J MATTHEW","position":1,"cik":"0001243514","reported_name":"SINGLETON J MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-10-25T19:27:22.000Z","date":"2024-10-25","kind":"exercise","planned":true,"acquired":true,"shares":16000,"price":4.48,"value":71680.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person."}],"balance_after":25500,"source":{"system":"sec-edgar","filing":"0000950170-24-117513","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1243514/000095017024117513/ownership.xml","form_type":"4"}},{"id":1401508,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70279,"kind":"person","name":"SINGLETON J MATTHEW","position":1,"cik":"0001243514","reported_name":"SINGLETON J MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-20T21:21:52.000Z","date":"2024-09-20","kind":"exercise","planned":true,"acquired":false,"shares":10300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person."}],"balance_after":0,"derivative":{"exercise_price":1.19,"exercise_date":"2018-01-03","expiration_date":"2027-01-03","underlying":"Common Stock","underlying_shares":10300},"source":{"system":"sec-edgar","filing":"0000950170-24-108577","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1243514/000095017024108577/ownership.xml","form_type":"4"}},{"id":1401507,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70279,"kind":"person","name":"SINGLETON J MATTHEW","position":1,"cik":"0001243514","reported_name":"SINGLETON J MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-09-20T21:21:52.000Z","date":"2024-09-20","kind":"sale","planned":true,"acquired":false,"shares":10300,"price":69.5,"value":715850.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person."}],"balance_after":9500,"source":{"system":"sec-edgar","filing":"0000950170-24-108577","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1243514/000095017024108577/ownership.xml","form_type":"4"}},{"id":1401506,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70279,"kind":"person","name":"SINGLETON J MATTHEW","position":1,"cik":"0001243514","reported_name":"SINGLETON J MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-09-20T21:21:52.000Z","date":"2024-09-20","kind":"exercise","planned":true,"acquired":true,"shares":10300,"price":1.19,"value":12257.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person."}],"balance_after":19800,"source":{"system":"sec-edgar","filing":"0000950170-24-108577","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1243514/000095017024108577/ownership.xml","form_type":"4"}},{"id":1425121,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70279,"kind":"person","name":"SINGLETON J MATTHEW","position":1,"cik":"0001243514","reported_name":"SINGLETON J MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-22T19:23:37.000Z","date":"2024-08-21","kind":"exercise","planned":true,"acquired":false,"shares":5700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person."}],"balance_after":10300,"derivative":{"exercise_price":1.19,"exercise_date":"2018-01-03","expiration_date":"2027-01-03","underlying":"Common Stock","underlying_shares":5700},"source":{"system":"sec-edgar","filing":"0000950170-24-099980","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1243514/000095017024099980/ownership.xml","form_type":"4"}},{"id":1425120,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70279,"kind":"person","name":"SINGLETON J MATTHEW","position":1,"cik":"0001243514","reported_name":"SINGLETON J MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-08-22T19:23:37.000Z","date":"2024-08-21","kind":"sale","planned":true,"acquired":false,"shares":5700,"price":69.7246,"value":397430.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.50 to $69.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":9500,"source":{"system":"sec-edgar","filing":"0000950170-24-099980","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1243514/000095017024099980/ownership.xml","form_type":"4"}},{"id":1425119,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70279,"kind":"person","name":"SINGLETON J MATTHEW","position":1,"cik":"0001243514","reported_name":"SINGLETON J MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-08-22T19:23:37.000Z","date":"2024-08-21","kind":"exercise","planned":true,"acquired":true,"shares":5700,"price":1.19,"value":6783.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person."}],"balance_after":15200,"source":{"system":"sec-edgar","filing":"0000950170-24-099980","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1243514/000095017024099980/ownership.xml","form_type":"4"}},{"id":1429078,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70279,"kind":"person","name":"SINGLETON J MATTHEW","position":1,"cik":"0001243514","reported_name":"SINGLETON J MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-19T20:11:47.000Z","date":"2024-08-19","kind":"exercise","planned":true,"acquired":false,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person."}],"balance_after":0,"derivative":{"exercise_price":3.33,"exercise_date":"2017-01-04","expiration_date":"2026-01-04","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0000950170-24-098799","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1243514/000095017024098799/ownership.xml","form_type":"4"}},{"id":1429077,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70279,"kind":"person","name":"SINGLETON J MATTHEW","position":1,"cik":"0001243514","reported_name":"SINGLETON J MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-08-19T20:11:47.000Z","date":"2024-08-19","kind":"sale","planned":true,"acquired":false,"shares":1501,"price":64.8798,"value":97384.5798,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.79 to $64.9056, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":9500,"source":{"system":"sec-edgar","filing":"0000950170-24-098799","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1243514/000095017024098799/ownership.xml","form_type":"4"}},{"id":1429076,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70279,"kind":"person","name":"SINGLETON J MATTHEW","position":1,"cik":"0001243514","reported_name":"SINGLETON J MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-08-19T20:11:47.000Z","date":"2024-08-19","kind":"sale","planned":true,"acquired":false,"shares":2388,"price":64.1037,"value":153079.6356,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.64 to $64.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":11001,"source":{"system":"sec-edgar","filing":"0000950170-24-098799","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1243514/000095017024098799/ownership.xml","form_type":"4"}},{"id":1429075,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70279,"kind":"person","name":"SINGLETON J MATTHEW","position":1,"cik":"0001243514","reported_name":"SINGLETON J MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-08-19T20:11:47.000Z","date":"2024-08-19","kind":"sale","planned":true,"acquired":false,"shares":2055,"price":63.1509,"value":129775.0995,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.635 to $63.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":13389,"source":{"system":"sec-edgar","filing":"0000950170-24-098799","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1243514/000095017024098799/ownership.xml","form_type":"4"}},{"id":1429074,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70279,"kind":"person","name":"SINGLETON J MATTHEW","position":1,"cik":"0001243514","reported_name":"SINGLETON J MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-08-19T20:11:47.000Z","date":"2024-08-19","kind":"sale","planned":true,"acquired":false,"shares":4509,"price":61.861,"value":278931.249,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.5874 to $62.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":15444,"source":{"system":"sec-edgar","filing":"0000950170-24-098799","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1243514/000095017024098799/ownership.xml","form_type":"4"}},{"id":1429073,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70279,"kind":"person","name":"SINGLETON J MATTHEW","position":1,"cik":"0001243514","reported_name":"SINGLETON J MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-08-19T20:11:47.000Z","date":"2024-08-19","kind":"sale","planned":true,"acquired":false,"shares":3047,"price":61.1251,"value":186248.1797,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.5411 to $61.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":19953,"source":{"system":"sec-edgar","filing":"0000950170-24-098799","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1243514/000095017024098799/ownership.xml","form_type":"4"}},{"id":1429072,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70279,"kind":"person","name":"SINGLETON J MATTHEW","position":1,"cik":"0001243514","reported_name":"SINGLETON J MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-08-19T20:11:47.000Z","date":"2024-08-19","kind":"sale","planned":true,"acquired":false,"shares":2500,"price":60.0138,"value":150034.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.50 to $60.3605, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":23000,"source":{"system":"sec-edgar","filing":"0000950170-24-098799","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1243514/000095017024098799/ownership.xml","form_type":"4"}},{"id":1429071,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70279,"kind":"person","name":"SINGLETON J MATTHEW","position":1,"cik":"0001243514","reported_name":"SINGLETON J MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-08-19T20:11:47.000Z","date":"2024-08-19","kind":"exercise","planned":true,"acquired":true,"shares":16000,"price":3.33,"value":53280.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person."}],"balance_after":25500,"source":{"system":"sec-edgar","filing":"0000950170-24-098799","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1243514/000095017024098799/ownership.xml","form_type":"4"}},{"id":1433490,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70279,"kind":"person","name":"SINGLETON J MATTHEW","position":1,"cik":"0001243514","reported_name":"SINGLETON J MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-14T20:03:56.000Z","date":"2024-08-14","kind":"exercise","planned":true,"acquired":false,"shares":20786,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person."}],"balance_after":0,"derivative":{"exercise_price":8,"exercise_date":"2016-05-26","expiration_date":"2025-04-28","underlying":"Common Stock","underlying_shares":20786},"source":{"system":"sec-edgar","filing":"0000950170-24-097325","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1243514/000095017024097325/ownership.xml","form_type":"4"}},{"id":1433489,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70279,"kind":"person","name":"SINGLETON J MATTHEW","position":1,"cik":"0001243514","reported_name":"SINGLETON J MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-08-14T20:03:56.000Z","date":"2024-08-14","kind":"sale","planned":true,"acquired":false,"shares":160,"price":58.3688,"value":9339.008,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.25 to $58.44, inclusive. The Reporting Person  undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":9500,"source":{"system":"sec-edgar","filing":"0000950170-24-097325","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1243514/000095017024097325/ownership.xml","form_type":"4"}},{"id":1433488,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70279,"kind":"person","name":"SINGLETON J MATTHEW","position":1,"cik":"0001243514","reported_name":"SINGLETON J MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-08-14T20:03:56.000Z","date":"2024-08-14","kind":"sale","planned":true,"acquired":false,"shares":20626,"price":57.5195,"value":1186397.207,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.20 to $58.14, inclusive. The Reporting Person  undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":9660,"source":{"system":"sec-edgar","filing":"0000950170-24-097325","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1243514/000095017024097325/ownership.xml","form_type":"4"}},{"id":1433487,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70279,"kind":"person","name":"SINGLETON J MATTHEW","position":1,"cik":"0001243514","reported_name":"SINGLETON J MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-08-14T20:03:56.000Z","date":"2024-08-14","kind":"exercise","planned":true,"acquired":true,"shares":20786,"price":8,"value":166288.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person."}],"balance_after":30286,"source":{"system":"sec-edgar","filing":"0000950170-24-097325","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1243514/000095017024097325/ownership.xml","form_type":"4"}},{"id":1687392,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70279,"kind":"person","name":"SINGLETON J MATTHEW","position":1,"cik":"0001243514","reported_name":"SINGLETON J MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-04T21:28:55.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":32000,"derivative":{"exercise_price":18.28,"exercise_date":"2025-01-02","expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001209191-24-000925","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1243514/000120919124000925/doc4.xml","form_type":"4"}},{"id":2066505,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70279,"kind":"person","name":"SINGLETON J MATTHEW","position":1,"cik":"0001243514","reported_name":"SINGLETON J MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-04T18:13:43.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":22000,"derivative":{"exercise_price":8.52,"exercise_date":"2024-01-03","expiration_date":"2033-01-03","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001209191-23-001314","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1243514/000120919123001314/doc4.xml","form_type":"4"}},{"id":2443354,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70279,"kind":"person","name":"SINGLETON J MATTHEW","position":1,"cik":"0001243514","reported_name":"SINGLETON J MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-05T19:11:33.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":22000,"derivative":{"exercise_price":4.88,"exercise_date":"2023-01-03","expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001209191-22-001985","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1243514/000120919122001985/doc4.xml","form_type":"4"}},{"id":2915089,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70279,"kind":"person","name":"SINGLETON J MATTHEW","position":1,"cik":"0001243514","reported_name":"SINGLETON J MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-06T16:39:44.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":22000,"derivative":{"exercise_price":5.8,"exercise_date":"2022-01-04","expiration_date":"2031-01-04","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001209191-21-002124","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1243514/000120919121002124/doc4.xml","form_type":"4"}},{"id":3322281,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70279,"kind":"person","name":"SINGLETON J MATTHEW","position":1,"cik":"0001243514","reported_name":"SINGLETON J MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-03T19:59:55.000Z","date":"2020-01-02","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":22000,"derivative":{"exercise_price":7.95,"exercise_date":"2021-01-02","expiration_date":"2030-01-02","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001209191-20-001422","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1243514/000120919120001422/doc4.xml","form_type":"4"}},{"id":3708181,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70279,"kind":"person","name":"SINGLETON J MATTHEW","position":1,"cik":"0001243514","reported_name":"SINGLETON J MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-01-03T20:27:37.000Z","date":"2019-01-02","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":22000,"derivative":{"exercise_price":8.32,"exercise_date":"2020-01-02","expiration_date":"2029-01-02","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001209191-19-001564","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1243514/000120919119001564/doc4.xml","form_type":"4"}},{"id":3912243,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70279,"kind":"person","name":"SINGLETON J MATTHEW","position":1,"cik":"0001243514","reported_name":"SINGLETON J MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2018-05-31T19:04:20.000Z","date":"2018-05-31","kind":"purchase","acquired":true,"shares":9500,"price":9.8169,"value":93260.55,"ownership":{"direct":true},"balance_after":9500,"source":{"system":"sec-edgar","filing":"0001209191-18-034496","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1243514/000120919118034496/doc4.xml","form_type":"4"}},{"id":4111016,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70279,"kind":"person","name":"SINGLETON J MATTHEW","position":1,"cik":"0001243514","reported_name":"SINGLETON J MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-01-03T16:17:42.000Z","date":"2018-01-02","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16000,"derivative":{"exercise_price":4.48,"exercise_date":"2019-01-02","expiration_date":"2028-01-02","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001209191-18-000853","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1243514/000120919118000853/doc4.xml","form_type":"4"}},{"id":4498093,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":70279,"kind":"person","name":"SINGLETON J MATTHEW","position":1,"cik":"0001243514","reported_name":"SINGLETON J MATTHEW","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-01-05T19:17:51.000Z","date":"2017-01-03","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16000,"derivative":{"exercise_price":1.19,"exercise_date":"2018-01-03","expiration_date":"2027-01-03","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001209191-17-002384","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1243514/000120919117002384/doc4.xml","form_type":"4"}}]}